Article (Scientific journals)
Real-world walking speed as a digital biomarker and outcome measure for clinical trials—a systematic review, regulatory status and future directions
Poleur, Margaux; Tychon, Cyril; Gilbert, Stephen et al.
2026In Frontiers in Digital Health, 8
Peer Reviewed verified by ORBi
 

Files


Full Text
fdgth-8-1726549.pdf
Publisher postprint (750.61 kB) Creative Commons License - Attribution
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[fr] Introduction Walking speed is a key measure of health and mobility across a wide range of diseases. Traditional gait assessments in clinical settings may not accurately reflect real-world mobility patterns. Wearable sensors offer an ecologically valid alternative by capturing every movement in daily life, but there are few robust, validated reports. We aimed to identify evidence on real-world gait speed measurements that have received or are seeking regulatory approval from agencies such as the European Medicines Agency and the U.S. Food and Drug Administration. Method We conducted a systematic review following a comprehensive search strategy using the Ovid platform, guided by pre-defined selection criteria and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We also manually searched the websites of key regulatory agencies and the ClinicalTrials.gov database. Results Our search identified 503 records, of which 10 met the inclusion criteria. Most studies were part of large-scale initiatives, including the qualification of the Stride Velocity 95th Centile and the MOBILISE-D project. No device or outcome measure that assesses walking speed in real-world conditions has been fully validated by the FDA. We found four letters of intent on the FDA website related to this concept. One outcome, the 95th centile of stride velocity, has been approved by the EMA as a primary endpoint for assessing ambulant patients with Duchenne Muscular Dystrophy. Conclusion Despite the potential of wearable devices to enhance drug development and clinical decision-making, real-world walking speed remains insufficiently validated across most conditions because data is missing. The widespread adoption of digital outcomes to assess ambulation will require extensive validation efforts, regulatory pathway adaptations, and improved standardization of devices, algorithms, and study methodologies. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42025633578 , PROSPERO CRD42025633578.
Disciplines :
Neurology
Author, co-author :
Poleur, Margaux  ;  Université de Liège - ULiège > Département des sciences cliniques ; University Department of Neurology, Citadelle Hospital
Tychon, Cyril ;  Université de Liège - ULiège > Faculté de Médecine > Master spéc. pédia.
Gilbert, Stephen;  Else Kröner Fresenius Center for Digital Health, TUD Dresden University of Technology ; Faculty of Business and Economics, TUD Dresden University of Technology
Daumer, Martin ;  SLCMSR E.V. - The Human Motion Institute
Servais, Laurent  ;  Université de Liège - ULiège > Département des sciences cliniques ; Department of Paediatrics, MDUK Oxford Neuromuscular Centre, University of Oxford
 These authors have contributed equally to this work.
Language :
French
Title :
Real-world walking speed as a digital biomarker and outcome measure for clinical trials—a systematic review, regulatory status and future directions
Publication date :
17 February 2026
Journal title :
Frontiers in Digital Health
eISSN :
2673-253X
Publisher :
Frontiers Media SA
Volume :
8
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 22 March 2026

Statistics


Number of views
67 (5 by ULiège)
Number of downloads
35 (1 by ULiège)

Scopus citations®
 
0
Scopus citations®
without self-citations
0
OpenAlex citations
 
0

Bibliography


Similar publications



Contact ORBi